eIF4B enhances ATF4 expression and contributes to cellular adaptation to asparagine limitation in BRAF-mutated A375 melanoma

Biochem Biophys Res Commun. 2021 Oct 8:573:93-99. doi: 10.1016/j.bbrc.2021.08.022. Epub 2021 Aug 10.

Abstract

ATF4 is a crucial transcription factor in the integrated stress response, a major adaptive signaling pathway activated by tumor microenvironment and therapeutic stresses. BRAF inhibitors, such as vemurafenib, induce ATF4 in BRAF-mutated melanoma cells, but the mechanisms of ATF4 induction are not fully elucidated. Here, we show that ATF4 expression can be upregulated by eukaryotic initiation factor 4B (eIF4B) in BRAF-mutated A375 cells. Indeed, eIF4B knockout (KO) prevented ATF4 induction and activation of the uORF-mediated ATF4 translation mechanism during vemurafenib treatment, which were effectively recovered by the rescue of eIF4B. Transcriptome analysis revealed that eIF4B KO selectively influenced ATF4-target gene expression among the overall gene expression changed by vemurafenib. Interestingly, eIF4B supported cellular proliferation under asparagine-limited conditions, possibly through the eIF4B-ATF4 pathway. Our findings indicate that eIF4B can regulate ATF4 expression, thereby contributing to cellular stress adaptation, which could be targeted as a therapeutic approach against malignancies, including melanoma.

Keywords: ATF4; Asparagine limitation; BRAF mutation; Melanoma; eIF4B; vemurafenib.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activating Transcription Factor 4 / genetics*
  • Activating Transcription Factor 4 / metabolism
  • Antineoplastic Agents / pharmacology
  • Asparagine / metabolism*
  • Cell Proliferation / drug effects
  • Eukaryotic Initiation Factors / deficiency
  • Eukaryotic Initiation Factors / metabolism*
  • Humans
  • Melanoma / drug therapy
  • Melanoma / genetics*
  • Melanoma / pathology
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins B-raf / metabolism
  • Tumor Cells, Cultured
  • Vemurafenib / pharmacology

Substances

  • ATF4 protein, human
  • Antineoplastic Agents
  • Eukaryotic Initiation Factors
  • eIF-4B
  • Activating Transcription Factor 4
  • Vemurafenib
  • Asparagine
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf